Open Access Highly Accessed Research article

Interactions between the adducin 2 gene and antihypertensive drug therapies in determining blood pressure in people with hypertension

Sharon LR Kardia1*, Yan V Sun1, Sara C Hamon2, Ruth Ann Barkley3, Eric Boerwinkle3 and Stephen T Turner4

Author Affiliations

1 Department of Epidemiology, University of Michigan, Ann Arbor, MI, USA

2 Department of Human Genetics, University of Michigan, Ann Arbor, MI, USA

3 Human Genetics Center, University of Texas Health Sciences Center, Houston, TX, USA

4 Department of Internal Medicine and Division of Hypertension, Mayo Clinic, Rochester, MN, USA

For all author emails, please log on.

BMC Medical Genetics 2007, 8:61  doi:10.1186/1471-2350-8-61

Published: 13 September 2007

Abstract

Background

As part of the NHLBI Family Blood Pressure Program, the Genetic Epidemiology Network of Arteriopathy (GENOA) recruited 575 sibships (n = 1583 individuals) from Rochester, MN who had at least two hypertensive siblings diagnosed before age 60. Linkage analysis identified a region on chromosome 2 that was investigated using 70 single nucleotide polymorphisms (SNPs) typed in 7 positional candidate genes, including adducin 2 (ADD2).

Method

To investigate whether blood pressure (BP) levels in these hypertensives (n = 1133) were influenced by gene-by-drug interactions, we used cross-validation statistical methods (i.e., estimating a model for predicting BP levels in one subgroup and testing it in a different subgroup). These methods greatly reduced the chance of false positive findings.

Results

Eight SNPs in ADD2 were significantly associated with systolic BP in untreated hypertensives (p-value < 0.05). Moreover, we also identified SNPs associated with gene-by-drug interactions on systolic BP in drug-treated hypertensives. The TT genotype at SNP rs1541582 was associated with an average systolic BP of 133 mmHg in the beta-blocker subgroup and 148 mmHg in the diuretic subgroup after adjusting for overall mean differences among drug classes.

Conclusion

Our findings suggest that hypertension candidate gene variation may influence BP responses to specific antihypertensive drug therapies and measurement of genetic variation may assist in identifying subgroups of hypertensive patients who will benefit most from particular antihypertensive drug therapies.